ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD)

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。ACCORD是一项多中心研究，将招募10,000名患有2型糖尿病和高血压或高脂血症的患者，这些患者有心血管（CV）疾病和/或bbb20 CV危险因素。受试者将被随机分配到标准（中位HbA1c为7.5%）或强化（中位HbA1c<6.0%）血糖控制组。此外，一项5800名参与者的2x2试验将评估贝特类药物治疗与他汀类药物治疗的结合。第二项纳入4200名患者的2x2试验将评估强化（收缩压<120 mmHg）与常规（收缩压<140mmHg）高血压治疗。受试者将被随访4-8年，主要结局是首次发生主要心血管事件，特别是非致命性心肌梗死、非致命性卒中或心血管死亡。糖尿病视网膜病变的发展或进展也将被评估

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. ACCORD is a multi-center study that will enroll 10,000 individuals with type-2 diabetes mellitus and either hypertension or hyperlipidemia who have cardiovascular (CV) disease and/or >2 CV risk factors. Subjects will be randomized to either standard (median HbA1c of 7.5%) or intensive (median HbA1c<6.0%) glycemic control. In addition one 2x2 trial of 5800 participants will evaluate the addition of fibrate therapy to statin therapy. A second 2x2 trial of 4200 patients will evaluate intensive (SBP<120 mmHg) versus conventional (SBP<140mmHg) hypertension therapy. Subjects will be followed for 4-8 years, with the primary outcome being the first occurrence of a major CV event, especially non fatal MI, non fatal stroke or CV death. The development or progression of diabetic retinopathy will also be evaluated